Drug Trial Radar · NCT05938296
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
29
Planned (sponsor's estimate)
Start
Dec 19, 2023
Primary completion
Dec 19, 2026
Study completion Dec 19, 2026
Sponsor
- Lead sponsor
- Binhui Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006 in patients with advanced solid tumors.
Conditions
- Solid Tumor
Interventions
BS006 InjectionDrug
BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AE (Adverse Event) and SAE (Serious Adverse Event)Time frame: Through study completion, an average of about 1 year(a maximum treatment duration of one year)
- MTDTime frame: up to 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orlando Health Cancer Institute
Orlando, Florida
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.